IE
HRTX icon

Israel Englander’s Heron Therapeutics HRTX Stock Holding History

Israel Englander’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-200,000
Closed -$3.8M – 3333
2016
Q1 		$3.8M Buy
+200,000
New +$3.95M 0.01% 1412

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's HRTX Position: Q2 2026 in Review

Israel Englander reduced its Heron Therapeutics (HRTX) stake by 47% in Q2 2026, selling an estimated $2.85M and leaving 4,070,101 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3925.

Israel Englander first reported a position in HRTX in Q1 2014 and has held it in 40 quarters since. The position peaked at $23.7M in Q2 2015. 161 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Israel Englander held 4,070,101 shares of Heron Therapeutics worth $1.74M as of Q2 2026.
  • Israel Englander sold 3,560,426 Heron Therapeutics shares in Q2 2026, an estimated $2.85M.
  • Heron Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3925 holding.
  • Israel Englander first reported a position in Heron Therapeutics in Q1 2014 and has held it in 40 quarters since.
  • Israel Englander's Heron Therapeutics position peaked at $23.7M in Q2 2015.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.